MF5

Due to increased life expectancy, most women live 40% of their life in menopause. 6,000 women in the US enter menopause daily. By 2025 that number will increase to 50 million in the US and 1.1 billion worldwide.

Most women experience symptoms that disturb their quality of life and experience health issues both prior to and post menopause. Approximately 75% of women experience hot flashes, sleep disturbance and mood swings following the menopause for an average duration of 7.5 years. Menopause hormone therapies (MHT) has been prescribed for decades. Unfortunately, despite its MHT’s efficacy in addressing menopausal symptoms it is associated with increased risk of breast cancer, stroke and early Alzheimer’s disease. Since these risks were elucidated 73% of women aged 40-65 are NOT currently treating their menopause symptoms, 68% have NOT used OTC vaginal treatments and 65% would NOT consider taking MHT.

MF5 is an estrogen receptor β-selective formula based on Based on Statistically significant Phase 2 results of Bionovo, Inc. botanical drug Menerba (MF101) under FDA IND. MF5 prevents breast and uterine cancer. MF5 does not increase the risk of clotting.

“Although MF-101 appears to be a promising therapeutic, the herbal composition of the drug may be a disadvantage... If these isolates were demonstrated to be as effective and safe in clinical trials as preliminary data suggest regarding MF-101, these compounds could change the way clinicians treat menopause-associated symptoms”

Stovall DW, Pinkerton JV. Curr Opin Investig Drugs. 2009 Apr;10(4):365-71.PMID: 19337958 Review.